The EU has exported 35 million vaccines, 9 million have been sent to the UK. The UK, which denies having an export ban, has exported none to the EU.
In a newsletter, European Council President Charles Michel claimed that the United Kingdom had imposed an “outright ban” on the export of vaccines or vaccine components. The claim was swiftly refuted by the UK’s foreign secretary, Dominic Raab, who described this view as “completely false” and demanded a meeting with the EU’s ambassador.
The ambassador was in Brussels, so his deputy, Nicole Mannion, met with the permanent under-secretary of the Foreign Office, Sir Philip Barton. A UK spokesperson said that they had discussed “incorrect assertions in recent EU communications”.
In a tweet, Michel appeared to partly acknowledge that “an outright ban” was an inaccurate description, writing that there were different ways to impose bans or restrictions on vaccines. He said that he hoped the UK’s reaction to his comments would result in more transparency and increased exports from the UK to the EU and other third countries.
An EU source has revealed that while the EU has exported 35 million vaccines, 9 million of which were sent to the UK, the UK has not exported any vaccines to the EU. At prime ministers questions, Boris Johnson said that the UK could be proud of its international response and wished to correct the suggestion that the UK had blocked vaccine exports: “let me be clear, we have not blocked the export of a single COVID-19 vaccine or vaccine components.”
A UK government spokesperson said: “The movement of vaccines and their components into and out of the UK is driven by contractual obligations vaccine suppliers have to their customers.
“These decisions are made by the manufacturers and the UK government does not restrict the free movement of these critical goods.”
We asked European Commision spokesperson, Eric Mamer, if the absence of UK to EU vaccine exports was tantamount to an outright ban. He replied: “It's not for us to comment on what is tantamount to a ban. What we know for certain is that we are a big player in terms of supplying doses of vaccines to our partners across the world and we certainly want this to continue.
“Of course, we hope that the global supply chains that help the production of vaccines will remain open so that everybody can benefit from the vaccine as quickly as possible.” He added that he expected that all companies that the EU had completed advance purchase agreements with would respect their commitments.
Europe well place to lead in the marathon that is vaccine rollout
In his newsletter, Charles Michel recognized that there had been strong criticism of national authorities and the EU over delays in the production and deployment of vaccines. He wrote that the EU was not lagging behind in a sprint, but “well placed to lead the field in a marathon”. He underlined how the EU’s approach was one of solidarity, guaranteeing a fair supply to all EU countries, by collective investment in a basket of different vaccines. The EU is also thinking ahead and investing in vaccines to deal with any future variants.
Michel highlighted the EU’s leading role in financing research, especially research into messenger RNA and as a major contributor to global efforts, with €2.7 billion committed by the EU and member states to the COVAX fund, for accessible and affordable vaccines - that amounts to 25% of its total funding. It has also pre-ordered 2 billion doses of vaccine for outside the EU. Europe is likely to be the leading producer of vaccines by the end of the year.
EU launches new strategy to develop therapeutic treatments for COVID-19
The European Commission has today (6 May) launched a strategy on COVID-19 therapeutics, including those for the treatment of ‘long COVID'. The strategy covers the full lifecycle of medicines: from research, development and manufacturing to procurement and deployment.
The Strategy’s target is to authorize three new therapeutics treatments for COVID-19 by October 2021 and possibly two further medicines by end of the year.
Health and Food Safety Commissioner Stella Kyriakides said: “Vaccinations save lives, but they cannot yet eradicate COVID-19. We need a strong push on treatments to limit the need for hospitalisation, speed up recovery times, and reduce mortality. Patients in Europe and across the world should have access to world-class COVID-19 medicines. This is why we have set a very clear goal: by October, we will develop and authorise three new effective COVID-19 therapeutics that can have the potential to change the course of the disease. We will do so by investing in research and innovation, the identification of new promising medicines, ramping up production capacity and supporting equitable access. Our Therapeutics Strategy is a strong European Health Union in action.”
A ‘therapeutics innovation booster' will be set up by July 2021 to support the most promising therapeutics from preclinical research to market authorization. Funds will be used to help countries set up and expedite clinical trials that meet the European Medicine Agency’s high standards. It is hoped that ten potential COVID-19 therapeutics and identify five of the most promising ones by June 2021.
The EU will also organize matchmaking events for industrial actors involved in therapeutics to ensure enough production capacity and swift manufacturing.
US supports WTO waiver of Intellectual Property on COVID-19 vaccines
In a surprise announcement by the US Trade Representative Katherine Tai has announced that the US supports the waiver of IP protections on COVID-19 vaccines to help end the pandemic and will “actively participate in WTO negotiations to make this happen”.
The USTR said that extraordinary times and circumstances called for extraordinary measures.
In March, European Commission trade spokesperson Miriam Garcia Ferrer told journalists that the current view of the European Union was that the problem of access to vaccines would not be resolved by waiving patent rights.
Garcia Ferrer said that the real problem lay in insufficient manufacturing capacity to produce the required quantities. The European Commission very much welcomed the statement of WTO Director-General Ngozi Okonjo-Iweala who has said there should be a third way to broaden access to vaccines through facilitating technology transfer within the multilateral rules, to encourage research and innovation while at the same time allowing licensing agreements that helped to scale up manufacturing capacities.
This morning European Commission President Ursula von der Leyen tweeted: "We are open to discuss any other effective and pragmatic solution. In this context we are ready to assess how the US proposal could help achieve that objective."
South African/Indian proposal
WTO members recently debated the proposal submitted by South Africa and India calling for a waiver from certain provisions of the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement in relation to the “prevention, containment or treatment” of COVID-19. Since its submission, the proposal has received further support from Kenya, Eswatini, Mozambique, Pakistan, Bolivia, Venezuela, Mongolia, Zimbabwe, Egypt and the African Group within the WTO.
The proponents argue that the waiving of certain obligations under the agreement would facilitate access to affordable medical products and the scaling-up of manufacturing and supply of essential medical products, until widespread vaccination is in place and the majority of the world’s population is immune.
However, there is a lack of consensus and divergence on what role intellectual property plays in achieving the goal of providing timely and secure access to safe, efficacious and affordable vaccines to all. Proponents argue that existing vaccine manufacturing capacities in the developing world remained unutilized because of IP barriers. Other delegations asked for concrete examples of where IP would pose a barrier that could not be addressed by existing TRIPS flexibilities.
The outgoing chair of the TRIPS Council, Ambassador Xolelwa Mlumbi-Peter of South Africa, said swift action is urgently required to help scale up COVID-19 vaccine production and distribution. She called on members to shift gears and move towards a solution-oriented discussion.
The next regular TRIPS Council meeting is scheduled for 8-9 June, but members agreed to consider additional meetings in April in order to assess potential progress on the IP waiver discussion.
Europe puts forward plan to reopen tourism to countries outside the EU
The European Commission has put forward a proposal on reopening non-essential travel from outside the EU. Tourism is one of the sectors that has been most hit by the pandemic and there is pressure from countries such as Greece, Cyprus and Spain to re-open as quickly as possible with the EU and to valuable markets outside the EU, like the British and Israelis.
In March, the EU outlined its approach to Europe's safe re-opening and agreed to keep the temporary restriction on non-essential travel into the EU under close review, and to propose amendments in line with relevant developments. The approach outlined reflects the latest scientific advice showing that vaccination considerably helps to break the transmission chain of the disease.
In parallel to preparing for the resumption of international travel for vaccinated travellers, the Commission proposed a ‘Digital Green Certificate’, showing proof that a person has been vaccinated against COVID-19, received a negative test result or recovered from COVID-19, to help facilitate safe and free movement inside the EU. This proposal also provides the basis for recognizing non-EU countries' vaccination certificates.
The Commission is proposing to allow entry to the EU for non-essential reasons, not only for all persons coming from countries with a good epidemiological situation, but also all people who have been fully vaccinated with an EU-authorised vaccine. This could be extended to vaccines having completed the WHO emergency use-listing process.
To reassure some EU countries, the European Commission is also proposing an ‘emergency brake' mechanism, to be co-ordinated at EU level that would allow states to act quickly and temporarily limit to a strict minimum all travel from any countries affected by any variant of the virus which raises concern.
The Council will take into consideration whether the third countries are also offering reciprocal measures for EU travellers.
Aviation/airlines5 days ago
Portugal extends COVID-19 air travel curbs until mid May
European elections4 days ago
Parti Popular wins Madrid snap election but fails to get majority
Business4 days ago
Antitrust: Commission sends Statement of Objections to Apple on App Store rules for music streaming providers
Belgium5 days ago
Police break up Brussels anti-lockdown party
Crime5 days ago
Four arrested in takedown of dark web child abuse platform with some half a million users
coronavirus5 days ago
EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated
Corporate tax rules4 days ago
Commission launches new learning portal for tax and customs professionals across the EU
EU4 days ago
Europe Day: Discover the European Union on occasion of 9 May